Russell Investments Group Ltd. Purchases 728,381 Shares of Bristol Myers Squibb Company $BMY

Russell Investments Group Ltd. grew its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 24.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 3,669,050 shares of the biopharmaceutical company’s stock after buying an additional 728,381 shares during the period. Russell Investments Group Ltd. owned 0.18% of Bristol Myers Squibb worth $165,107,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Gateway Investment Advisers LLC raised its holdings in Bristol Myers Squibb by 10.0% during the 3rd quarter. Gateway Investment Advisers LLC now owns 113,457 shares of the biopharmaceutical company’s stock valued at $5,117,000 after acquiring an additional 10,284 shares during the period. CWA Asset Management Group LLC grew its position in shares of Bristol Myers Squibb by 25.9% in the third quarter. CWA Asset Management Group LLC now owns 150,359 shares of the biopharmaceutical company’s stock valued at $6,781,000 after purchasing an additional 30,909 shares in the last quarter. Stephens Inc. AR grew its position in shares of Bristol Myers Squibb by 13.5% in the third quarter. Stephens Inc. AR now owns 273,343 shares of the biopharmaceutical company’s stock valued at $12,328,000 after purchasing an additional 32,476 shares in the last quarter. Railway Pension Investments Ltd raised its stake in shares of Bristol Myers Squibb by 3.7% during the 3rd quarter. Railway Pension Investments Ltd now owns 1,139,600 shares of the biopharmaceutical company’s stock valued at $51,396,000 after purchasing an additional 40,300 shares during the period. Finally, Norges Bank purchased a new stake in Bristol Myers Squibb during the 2nd quarter worth about $1,554,154,000. Hedge funds and other institutional investors own 76.41% of the company’s stock.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: U.S. FDA approved Sotyktu (deucravacitinib) for adults with active psoriatic arthritis — a label expansion that can broaden Sotyktu’s market opportunity and revenue runway. U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
• Positive Sentiment: BMY declared a quarterly dividend of $0.63/share (ex-dividend April 2), maintaining a high-yield payout that supports income-focused investors and can underpin the stock’s valuation. Dividend Announcement
• Positive Sentiment: Reblozyl showed positive Phase 2 results in alpha-thalassemia and has exceeded $2.3B in annualized sales — evidence Reblozyl is becoming a material growth driver as older drugs decline. Reblozyl Phase 2 Success Shapes Bristol Myers Squibb Valuation Story
• Neutral Sentiment: Bristol-Myers Squibb is tracking the real-world impact of KarXT in schizophrenia — useful clinical/market data but longer-term and unlikely to move near-term earnings. Bristol-Myers Squibb Tracks Real-World Impact of KarXT in Schizophrenia
• Negative Sentiment: Q4 results showed revenue roughly in line but EPS missed consensus (reported $1.26 vs. ~$1.65 expected), which prompted investor selling and weighed on the stock. Earnings and Market Reaction
• Negative Sentiment: Recent articles highlight a larger-than-market intraday decline and analyst focus on legacy-product pressures — shorter-term sentiment and volatility remain a risk until new product growth scales. Bristol Myers Squibb (BMY) Registers a Bigger Fall Than the Market

Analyst Ratings Changes

Several brokerages have commented on BMY. Leerink Partners raised their target price on Bristol Myers Squibb from $54.00 to $60.00 and gave the stock an “outperform” rating in a research note on Tuesday, January 13th. The Goldman Sachs Group reissued a “neutral” rating and issued a $57.00 price target (up from $51.00) on shares of Bristol Myers Squibb in a report on Tuesday, December 2nd. HSBC restated a “hold” rating and issued a $53.00 price objective on shares of Bristol Myers Squibb in a research report on Wednesday, December 10th. Citigroup boosted their price objective on shares of Bristol Myers Squibb from $60.00 to $64.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. Finally, Morgan Stanley reiterated an “underweight” rating and issued a $40.00 target price on shares of Bristol Myers Squibb in a research note on Friday, February 6th. Nine investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $61.00.

Bristol Myers Squibb Stock Performance

NYSE:BMY opened at $60.21 on Monday. The stock has a market cap of $122.62 billion, a P/E ratio of 17.45, a PEG ratio of 0.17 and a beta of 0.26. The company has a quick ratio of 1.14, a current ratio of 1.26 and a debt-to-equity ratio of 2.32. The business’s 50-day moving average price is $57.66 and its two-hundred day moving average price is $51.03. Bristol Myers Squibb Company has a twelve month low of $42.52 and a twelve month high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, February 5th. The biopharmaceutical company reported $1.26 EPS for the quarter, missing the consensus estimate of $1.65 by ($0.39). The business had revenue of $12.50 billion for the quarter, compared to analysts’ expectations of $12.24 billion. Bristol Myers Squibb had a return on equity of 69.65% and a net margin of 14.64%.The firm’s revenue for the quarter was up 1.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.67 EPS. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities analysts predict that Bristol Myers Squibb Company will post 6.74 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, May 1st. Stockholders of record on Thursday, April 2nd will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, April 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb’s dividend payout ratio (DPR) is 73.04%.

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.